The genomic and biological complexity of mixed phenotype acute leukemia

References

• Kung P, Goldstein G, Reinherz EL, et al. Monoclonal antibodies defining distinctive human T cell surface antigens. Science. 1979;206(4416):347–349.
   PubMed Web of Science ®Google Scholar
• Smith LJ, Curtis JE, Messner HA, et al. Lineage infidelity in acute leukemia. Blood. 1983;61(6):1138–1145.
   PubMed Web of Science ®Google Scholar
• Greaves MF, Chan LC, Furley AJ, et al. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood. 1986;67(1):1–11.
   PubMed Web of Science ®Google Scholar
• Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562(7727):373–379.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Wang F, Morita K, et al. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun. 2018;9(1):2670.
   PubMedGoogle Scholar
• Xiao W, Bharadwaj M, Levine M, et al. PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. Blood Adv. 2018;2(23):3526–3539.
   PubMed Web of Science ®Google Scholar
• Borowitz MJ, Bene M-C, Harris NL, et al. Acute leukemias of ambigous lineage. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Vol. 2. Revised 4th ed. Lyons (France): IARC; 2017. p. 180–185.
   Google Scholar
• Borowitz MJ, Bene MC, Harris NL, et al. Acute leukemias of ambiguous lineage. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Vol. 2. 4th ed. Lyon, (France): IARC; 2008. p. 149–155.
   Google Scholar
• Taussig DC, Pearce DJ, Simpson C, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086–4092.
   PubMed Web of Science ®Google Scholar
• Eissens DN, Spanholtz J, van der Meer A, et al. Defining early human NK cell developmental stages in primary and secondary lymphoid tissues. PLoS One. 2012;7(2):e30930.
   PubMed Web of Science ®Google Scholar
• Haubner S, Perna F, Kohnke T, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64–74.
   PubMed Web of Science ®Google Scholar
• Patel KP, Khokhar FA, Muzzafar T, et al. TdT expression in acute myeloid leukemia with minimal differentiation is associated with distinctive clinicopathological features and better overall survival following stem cell transplantation. Mod Pathol. 2013;26(2):195–203.
   PubMed Web of Science ®Google Scholar
• Wolach O, Stone RM. How I treat mixed-phenotype acute leukemia. Blood. 2015;125(16):2477–2485.
   PubMed Web of Science ®Google Scholar
• Bene MC. Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias! Haematologica. 2009;94(7):891–893.
   PubMed Web of Science ®Google Scholar
• Hrusak O, de Haas V, Stancikova J, et al. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. Blood. 2018;132(3):264–276.
   PubMed Web of Science ®Google Scholar
• Wolach O, Stone RM. Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy. Curr Opin Hematol. 2017;24(2):139–145.
   PubMed Web of Science ®Google Scholar
• Patel SS, Weinberg OK. Diagnostic workup of acute leukemias of ambiguous lineage. Am J Hematol. 2020;95(6):718–722.
   PubMed Web of Science ®Google Scholar
• Matarraz S, Lopez A, Barrena S, et al. The immunophenotype of different immature, myeloid and B-cell lineage-committed CD34+ hematopoietic cells allows discrimination between normal/reactive and myelodysplastic syndrome precursors. Leukemia. 2008;22(6):1175–1183.
   PubMed Web of Science ®Google Scholar
• Guy J, Antony-Debre I, Benayoun E, et al. Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. Br J Haematol. 2013;161(4):551–555.
   PubMed Web of Science ®Google Scholar
• van den Ancker W, Westers TM, de Leeuw DC, et al. A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin. Cytometry. 2013;84B(2):114–118.
   Google Scholar
• Serrano J, Roman J, Jimenez A, et al. Genetic, phenotypic and clinical features of acute lymphoblastic leukemias expressing myeloperoxidase mRNA detected by RT-PCR. Leukemia. 1999;13(2):175–180.
   PubMed Web of Science ®Google Scholar
• Oberley MJ, Li S, Orgel E, et al. Clinical significance of isolated myeloperoxidase expression in pediatric B-lymphoblastic leukemia. Am J Clin Pathol. 2017;147(4):374–381.
   PubMed Web of Science ®Google Scholar
• Porwit A, Bene MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia. Cytometry B Clin Cytom. 2019;96(3):183–194.
   PubMed Web of Science ®Google Scholar
• Porwit A, Bene MC. Multiparameter flow cytometry applications in the diagnosis of mixed phenotype acute leukemia (MPAL.). Cytometry. 2019;96(3):183–194.
   PubMedGoogle Scholar
• Hoehn D, Medeiros LJ, Chen SS, et al. CD117 expression is a sensitive but nonspecific predictor of FLT3 mutation in T acute lymphoblastic leukemia and T/myeloid acute leukemia. Am J Clin Pathol. 2012;137(2):213–219.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ding L, Holmfeldt L, et al. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature. 2012;481(7380):157–163.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Buldini B, Gaipa G, et al. AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia. Cytometry B Clin Cytom. 2018;94(1):82–93.
   PubMed Web of Science ®Google Scholar
• Owaidah TM, Al Beihany A, Iqbal MA, et al. Cytogenetics, molecular and ultrastructural characteristics of biphenotypic acute leukemia identified by the EGIL scoring system. Leukemia. 2006;20(4):620–626.
   PubMed Web of Science ®Google Scholar
• Yan L, Ping N, Zhu M, et al. Clinical, immunophenotypic, cytogenetic, and molecular genetic features in 117 adult patients with mixed-phenotype acute leukemia defined by WHO-2008 classification. Haematologica. 2012;97(11):1708–1712.
   PubMed Web of Science ®Google Scholar
• Weinberg OK, Seetharam M, Ren L, et al. Mixed phenotype acute leukemia: a study of 61 cases using World Health Organization and European Group for the immunological classification of leukaemias criteria. Am J Clin Pathol. 2014;142(6):803–808.
   PubMed Web of Science ®Google Scholar
• Shi R, Munker R. Survival of patients with mixed phenotype acute leukemias: a large population-based study. Leuk Res. 2015;39(6):606–616.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gu M, Mi Y, et al. Clinical characteristics and outcomes of mixed phenotype acute leukemia with Philadelphia chromosome positive and/or bcr-abl positive in adult. Int J Hematol. 2011;94(6):552–555.
   PubMed Web of Science ®Google Scholar
• Matutes E, Pickl WF, Van’t Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011;117(11):3163–3171.
   PubMed Web of Science ®Google Scholar
• Lafage-Pochitaloff M, Baranger L, Hunault M, et al. Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. Blood. 2017;130(16):1832–1844.
   PubMed Web of Science ®Google Scholar
• Kresch MP, Xiao W, Menghrajani K, et al. Acute leukemia with lineage infidelity: mixed phenotype AML exhibits a distinct immunophenotype with clinical features overlapping mixed phenotype acute leukemia. Blood. 2019;134(Supplement_1):2718.
   Google Scholar
• Challen GA, Sun D, Jeong M, et al. Dnmt3a is essential for hematopoietic stem cell differentiation. Nat Genet. 2011;44(1):23–31.
   PubMed Web of Science ®Google Scholar
• Bolouri H, Farrar JE, Triche T, Jr, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103–112.
   PubMed Web of Science ®Google Scholar
• Liu YF, Wang BY, Zhang WN, et al. Genomic profiling of adult and pediatric B-cell acute lymphoblastic leukemia. EBioMedicine. 2016;8:173–183.
   PubMed Web of Science ®Google Scholar
• Velten L, Haas SF, Raffel S, et al. Human haematopoietic stem cell lineage commitment is a continuous process. Nat Cell Biol. 2017;19(4):271–281.
   PubMed Web of Science ®Google Scholar
• Pomerantz A, Rodriguez-Rodriguez S, Demichelis-Gomez R, et al. Mixed-phenotype acute leukemia: suboptimal treatment when the 2008/2016 WHO classification is used. Blood Res. 2016;51(4):233–241.
   PubMed Web of Science ®Google Scholar
• Maruffi M, Sposto R, Oberley MJ, et al. Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis. Leukemia. 2018;32(7):1515–1528.
   PubMed Web of Science ®Google Scholar
• Munker R, Labopin M, Esteve J, et al. Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. a retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica. 2017;102(12):2134–2140.
   PubMed Web of Science ®Google Scholar
• Munker R, Brazauskas R, Wang HL, et al. Allogeneic hematopoietic cell transplantation for patients with mixed phenotype acute leukemia. Biol Blood Marrow Transplant. 2016;22(6):1024–1029.
   PubMed Web of Science ®Google Scholar
• Getta BM, Roshal M, Zheng J, et al. Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning is associated with favorable outcomes in mixed phenotype acute leukemia. Biol Blood Marrow Transplant. 2017;23(11):1879–1886.
   PubMed Web of Science ®Google Scholar
• Andrews C, Atenafu EG, Murphy T, et al. Allogeneic stem cell transplantation has limited benefit in older patients with mixed phenotype acute leukemia. Blood. 2019;134(Supplement_1):5725.
   Google Scholar
• Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123(6):843–850.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Yokohama A, Hatsumi N, et al. Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol. 2014;93(4):297–301.
   PubMed Web of Science ®Google Scholar
• Couban S, Savoie L, Mourad YA, et al. Evidence-based guidelines for the use of tyrosine kinase inhibitors in adults with Philadelphia chromosome-positive or BCR-ABL-positive acute lymphoblastic leukemia: a Canadian consensus. Curr Oncol. 2014;21(2):e265–e309.
   PubMed Web of Science ®Google Scholar
• Saini L, Brandwein J. New treatment strategies for Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2017;12(2):136–142.
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464.
   PubMed Web of Science ®Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740.
   PubMed Web of Science ®Google Scholar
• DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Stevens BM, Jones CL, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24(12):1859–1866.
   PubMed Web of Science ®Google Scholar
• Khan N, Hills RK, Knapper S, et al. Normal hematopoietic progenitor subsets have distinct reactive oxygen species, BCL2 and cell-cycle profiles that are decoupled from maturation in acute myeloid leukemia. PLoS One. 2016;11(9):e0163291.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
   PubMed Web of Science ®Google Scholar
• El Chaer F, Ali OM, Sausville EA, et al. Treatment of CD19-positive mixed phenotype acute leukemia with blinatumomab. Am J Hematol. 2019;94(1):e7–e8.
   PubMed Web of Science ®Google Scholar
• Durer S, Durer C, Shafqat M, et al. Concomitant use of blinatumomab and donor lymphocyte infusion for mixed-phenotype acute leukemia: a case report with literature review. Immunotherapy. 2019;11(5):373–378.
   PubMed Web of Science ®Google Scholar
• Jongen-Lavrencic M, Grob T, Hanekamp D, et al. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018;378(13):1189–1199.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153–4162.
   PubMed Web of Science ®Google Scholar
• Oberley MJ, Raikar SS, Wertheim GB, et al. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multicenter cohort study. Leukemia. 2020;34(7):1741–1750.
   PubMed Web of Science ®Google Scholar
• Charles NJ, Boyer DF. Mixed-phenotype acute leukemia: diagnostic criteria and pitfalls. Arch Pathol Lab Med. 2017;141(11):1462–1468.
   PubMed Web of Science ®Google Scholar
• Shimizu H, Saitoh T, Machida S, et al. Allogeneic hematopoietic stem cell transplantation for adult patients with mixed phenotype acute leukemia: results of a matched-pair analysis. Eur J Haematol. 2015;95(5):455–460.
   PubMed Web of Science ®Google Scholar
• Minervini CF, Cumbo C, Orsini P, et al. Nanopore sequencing in blood diseases: a wide range of opportunities. Front Genet. 2020;11:76.
   PubMed Web of Science ®Google Scholar